SCHEMBL8344451

SCHEMBL8344451

Oc1c(-c2ccccc2F)cc(-c2ccccc2F)c2cccnc12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.66
PIK3CD O00329 1/20 0.48
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
TDP1 Q9NUW8 5/20 0.47
ALDH1A1 P00352 4/20 0.47
LMNA P02545 4/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
MAPT P10636 3/20 0.47
POLB P06746 1/20 0.47
THRB P10828 1/20 0.47
PKM P14618 1/20 0.47
IDO1 P14902 1/20 0.47
RECQL P46063 1/20 0.47
TDO2 P48775 1/20 0.47
BLM P54132 1/20 0.47
CASP6 P55212 1/20 0.47
MPI P34949 1/20 0.46
HSP90AA1 P07900 5/20 0.45
TP53 P04637 4/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8339373 0.87 KDM4E (0.61) KDM4EPIK3CDMEN1KMT2ATDP1
SCHEMBL8345105 0.87 KDM4E (0.60) KDM4EMEN1KMT2ATDP1ALDH1A1
SCHEMBL8344969 0.81 HTT (0.46) KDM4EPIK3CDMEN1KMT2ATDP1
SCHEMBL19891726 0.81 PIK3CD (0.48) KDM4EPIK3CDMEN1KMT2ATDP1
SCHEMBL8344448 0.81 MEN1 (0.47) KDM4EPIK3CDMEN1KMT2ATDP1
SCHEMBL16407664 0.78 KDM4E (0.42) KDM4EPIK3CDMEN1KMT2ATDP1
SCHEMBL8344364 0.78 HSP90AA1 (0.47) KDM4EPIK3CDMEN1KMT2ATDP1
SCHEMBL17278914 0.76 COMT (0.49) KDM4EPIK3CDMEN1KMT2ATDP1
SCHEMBL6051226 0.76 PIK3CD (0.59) KDM4EPIK3CDMEN1KMT2ATDP1
SCHEMBL19891758 0.75 PIK3CD (0.51) KDM4EPIK3CDMEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 US disclosed
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 US disclosed
US-9302993-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2016-04-05 US disclosed
US-9302993-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2016-04-05 US disclosed
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-11-26 US disclosed
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-11-26 US disclosed
US-9169211-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2015-10-27 US disclosed
US-9169211-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2015-10-27 US disclosed
US-20150094334-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-04-02 US disclosed
US-20150094334-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-04-02 US disclosed
US-20150025108-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-01-22 US disclosed
US-8163760-B2 Use of pyridopyrimidine compounds in the treatment of gliomas PRANA BIOTECHNOLOGY LIMITED (AU) 2012-04-24 US disclosed
US-8163760-B2 Use of pyridopyrimidine compounds in the treatment of gliomas PRANA BIOTECHNOLOGY LIMITED (AU) 2012-04-24 US disclosed
US-20100069393-A1 METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME PRANA BIOTECHNOLOGY LIMITED (AU) 2010-03-18 US disclosed
US-20100069393-A1 METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME PRANA BIOTECHNOLOGY LIMITED (AU) 2010-03-18 US disclosed
US-7619091-B2 Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) PRANA BIOTECHNOLOGY LIMITED (AU) 2009-11-17 US disclosed
US-7619091-B2 Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) PRANA BIOTECHNOLOGY LIMITED (AU) 2009-11-17 US disclosed
US-20080161353-A1 8-Hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2008-07-03 US disclosed
US-20080161353-A1 8-Hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2008-07-03 US disclosed
WO-2004007461-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069393-A1 METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME MGMT, DHFR, IDH2 KDM4E 2823/4885PIK3CD 4550/4885MEN1 83/4885
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PARK7, COQ8A, NLN KDM4E 3604/4885PIK3CD 4686/4885MEN1 1871/4885
US-20080161353-A1 8-Hydroxy quinoline derivatives PARK7, COQ8A, NLN KDM4E 3604/4885PIK3CD 4686/4885MEN1 1871/4885
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression TERT, TERF2, RNGTT KDM4E 1300/4885PIK3CD 4156/4885MEN1 3550/4885
US-20150025108-A1 8-HYDROXY QUINOLINE DERIVATIVES PARK7, COQ8A, NLN KDM4E 3604/4885PIK3CD 4686/4885MEN1 1871/4885
US-20150094334-A1 8-HYDROXY QUINOLINE DERIVATIVES PARK7, COQ8A, NLN KDM4E 3604/4885PIK3CD 4686/4885MEN1 1871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.